For citations:
Kulyova S.A., Varfolomeeva S.R., Kirgizov K.I., Prosekina E.A., Romantsova O.M., Gorbunova T.V. A phase III, multicenter, open-label study of dinutuximab beta without/with chemotherapy at the investigator’s choice in patients under 18 years old with bone and soft tissue sarcomas with positive expression GD2 and disease progression during the first-line chemotherapy. Russian Journal of Pediatric Hematology and Oncology. 2024;11(2):12-20. (In Russ.) https://doi.org/10.21682/2311-1267-2024-11-2-12-20